Wei Xue

Title: Wei Xue - Innovator in Cancer Immunotherapy

Introduction

Wei Xue is a notable inventor based in Oxfordshire, GB. He has made significant contributions to the field of cancer immunotherapy through his innovative research and patent developments. His work focuses on the use of epitopes containing homocitrulline, which have the potential to revolutionize cancer treatment.

Latest Patents

Wei Xue holds a patent related to epitopes that can be utilized as targets for cancer immunotherapy. The invention details homocitrullinated T cell epitopes that possess a predicted binding score to MIC class II or class I of less than 30, as determined by the online IEDB prediction program. These epitopes feature at least five consecutive amino acids that form a spiral conformational structure. The modified peptides developed from this research can serve as vaccines or targets for T cell receptor (TCR) and adoptive T cell transfer therapies. He has 1 patent to his name.

Career Highlights

Wei Xue is currently associated with Scancell Limited, where he continues to advance his research in immunotherapy. His work is pivotal in the ongoing efforts to develop effective cancer treatments that harness the body's immune system.

Collaborations

Wei collaborates with Katherine Wendy Cook, contributing to the innovative research environment at Scancell Limited. Their combined expertise enhances the potential for breakthroughs in cancer immunotherapy.

Conclusion

Wei Xue's contributions to the field of cancer immunotherapy through his innovative patent and collaboration with colleagues highlight his commitment to advancing medical science. His work has the potential to significantly impact cancer treatment methodologies in the future.